We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at ...

Sana Biotechnology (SANA), a clinical-stage biotech company specializing in gene and cell therapies, has recently experienced ...

On Tuesday, Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $2.92 which represents a decrease of $-0.24 or -7.59% from the prior close of $3.16. The stock opened at $3.17 and ...

As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...

Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $3.16 which represents a decrease of $-0.09 or -2.77% from the prior close of $3.25. The stock opened at $3.15 and touched a low of ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology (NASDAQ:SANA – Free Report) had its price target boosted by HC Wainwright from $8.00 to $11.00 in a report ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated look at SANA stock following its news.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

BofA lowered the firm’s price target on Sana Biotechnology (SANA) to $7 from $8 and keeps a Buy rating on the shares. While political and rate uncertainty continues to be an overhang ...

Sana announced that its primary islet cell therapy, UP421, had been successfully implanted into a Type 1 diabetes patient.

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells ...